Loading clinical trials...
Loading clinical trials...
The Effect of Hepatic Impairment on The Pharmacokinetics of Seladelpar: An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment
Conditions
Interventions
Seladelpar 10 mg
Seladelpar 10 mg or less
Locations
20
United States
Arizona Liver Health
Chandler, Arizona, United States
University of California Davis
Sacramento, California, United States
University of Colorado Anschutz
Aurora, Colorado, United States
Mercy Medical Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Henry Ford Health System
Novi, Michigan, United States
Start Date
September 17, 2021
Primary Completion Date
February 24, 2025
Completion Date
February 27, 2025
Last Updated
March 17, 2025
NCT07324616
NCT07304843
NCT07449793
NCT07023354
NCT04271488
NCT05751967
Lead Sponsor
Gilead Sciences
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions